Document Detail


Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
MedLine Citation:
PMID:  17113426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim of assessing relative cardiovascular risk of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs). The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac. METHODS: We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). The primary hypothesis stated that etoricoxib is not inferior to diclofenac, defined as an upper boundary of less than 1.30 for the 95% CI of the hazard ratio for thrombotic cardiovascular events in the per-protocol analysis. Intention-to-treat analyses were also done to assess consistency of results. These trials are registered at http://www.clinicaltrials.gov with the numbers NCT00092703, NCT00092742, and NCT00250445. FINDINGS: 34 701 patients (24 913 with osteoarthritis and 9 787 with rheumatoid arthritis) were enrolled. Average treatment duration was 18 months (SD 11.8). 320 patients in the etoricoxib group and 323 in the diclofenac group had thrombotic cardiovascular events, yielding event rates of 1.24 and 1.30 per 100 patient-years and a hazard ratio of 0.95 (95% CI 0.81-1.11) for etoricoxib compared with diclofenac. Rates of upper gastrointestinal clinical events (perforation, bleeding, obstruction, ulcer) were lower with etoricoxib than with diclofenac (0.67 vs 0.97 per 100 patient-years; hazard ratio 0.69 [0.57-0.83]), but the rates of complicated upper gastrointestinal events were similar for etoricoxib (0.30) and diclofenac (0.32). INTERPRETATION: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.
Authors:
Christopher P Cannon; Sean P Curtis; Garret A FitzGerald; Henry Krum; Amarjot Kaur; James A Bolognese; Alise S Reicin; Claire Bombardier; Michael E Weinblatt; Désirée van der Heijde; Erland Erdmann; Loren Laine;
Related Documents :
20039456 - Electro-acupuncture to prevent prolonged postoperative ileus: a randomized clinical trial.
1252976 - The results of therapeutic acupuncture in a pain clinic.
2155756 - Comparative efficacy and tolerability of two antibacterial/anti-inflammatory formulatio...
18570266 - Effect of pine bark extract (pycnogenol) on symptoms of knee osteoarthritis.
21044326 - Lumbsten: the lumbar spinal stenosis outcome study.
11198366 - Igm and igg cystatin capture enzyme linked immunosorbent assays: a tool for serodiagnos...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  368     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-11-20     Completed Date:  2006-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1771-81     Citation Subset:  AIM; IM    
Affiliation:
Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. cpcannon@partners.org
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00092703;  NCT00092742;  NCT00250445
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Cardiovascular Diseases / chemically induced
Cyclooxygenase 2 Inhibitors / adverse effects,  therapeutic use*
Diclofenac / adverse effects,  therapeutic use*
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Osteoarthritis / drug therapy*
Pyridines / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Sulfones / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Pyridines; 0/Sulfones; 15307-86-5/Diclofenac; 202409-33-4/etoricoxib
Comments/Corrections
Comment In:
Lancet. 2006 Nov 18;368(9549):1745-7   [PMID:  17113403 ]
Nat Clin Pract Rheumatol. 2007 Jun;3(6):316-7   [PMID:  17406384 ]
ACP J Club. 2007 Mar-Apr;146(2):44   [PMID:  17335167 ]
Lancet. 2007 Feb 17;369(9561):555-6; author reply 556   [PMID:  17307095 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Beyond diuretics: management of volume overload in acute heart failure syndromes.
Next Document:  Unintended pregnancy and use of emergency contraception among a large cohort of women attending for ...